Latest news with #Alkem
&w=3840&q=100)
Business Standard
13-06-2025
- Business
- Business Standard
IPO-bound Allchem in legal tussle with Alkem over trademark infringement
IPO-bound Allchem Lifesciences adds legal dispute with Alkem to DRHP as Delhi HC directs both firms to mediation and next hearing is scheduled for 9 July Sanket Koul New Delhi Listen to This Article Vadodara-based Allchem Lifesciences on Friday issued an addendum to its draft red herring prospectus (DRHP) with the Securities and Exchange Board of India (Sebi), highlighting a suit filed by Alkem Laboratories against it in the Delhi High Court. The suit, filed on 23 April, alleges infringement of Alkem Labs' trademark with respect to the use of the name Allchem by the initial public offering (IPO)-bound company. In its submission to the Delhi HC, Alkem has sought a permanent injunction on the use of the name 'Allchem' and the offer under this name, along with damages of ₹2 crore for the
Business Upturn
04-06-2025
- Business
- Business Upturn
Alkem Labs shares trade lower after Rs 856 crore block deal
By Aditya Bhagchandani Published on June 4, 2025, 09:31 IST Shares of Alkem Laboratories came into focus on Tuesday following a large block deal worth ₹856.39 crore executed on the BSE. The transaction involved the exchange of approximately 17.49 lakh shares at a price of ₹4,895.60 per share. Ahead of the trade, reports had indicated that Jayanti Sinha, a member of the promoter group, was planning to offload a 1.42% stake in the company. As per the March 2025 shareholding data, Sinha held a 2.46% stake in Alkem Laboratories. The block deal, executed at a floor price of ₹4,850, was offered at a nearly 3% discount to the last traded price. Promoters hold a controlling 55.1% stake in Alkem, while foreign institutional investors (FIIs) and domestic institutional investors (DIIs) own 9.4% and 19.4% stakes respectively. The public holds the remaining 16.1% of the equity. Financially, Alkem Labs reported a 4.2% year-on-year increase in net profit to ₹305.9 crore for the March quarter. Revenue rose 7.1% to ₹3,143.8 crore, but EBITDA margins saw a decline to 12.4% from 13.7% last year, leading to some investor disappointment. Disclaimer: The information provided is for informational purposes only and should not be considered financial or investment advice. Stock market investments are subject to market risks. Always conduct your own research or consult a financial advisor before making investment decisions. Author or Business Upturn is not liable for any losses arising from the use of this information. Aditya Bhagchandani serves as the Senior Editor and Writer at Business Upturn, where he leads coverage across the Business, Finance, Corporate, and Stock Market segments. With a keen eye for detail and a commitment to journalistic integrity, he not only contributes insightful articles but also oversees editorial direction for the reporting team.
